drugset

drugset / Trial / NCT03440034

Study of Pioglitazone in Sporadic Inclusion Body Myositis

NCT03440034 ↗

Phase 1 Completed 19 enrolled Johns Hopkins University

NaSingle-groupOpen-labelBasic science

Summary

A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

Timeline

Start: 2018-05-22
Primary completion: 2020-12-31
Completion: 2020-12-31

Publications

Adler BL, Bene MR, Zhang C, Say C, Khare P, Mecoli C, Tiniakou E, Paik JJ, Chung T, Darrah E, Lloyd T, Pagkatipunan R, McGowan M, Mears A, Vernon HJ, Christopher-Stine L, Le A, Albayda J. Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial. Nat Commun. 2026 Mar 15;17(1):3995. doi: 10.1038/s41467-026-70262-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	45 mg	Oral

Indications